Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Lexaria Bioscience's share price for the quarter that ended in May. 2026 was $0.602. Lexaria Bioscience's Shares Outstanding (EOP) for the quarter that ended in May. 2026 was 24.79 Mil. Therefore, Lexaria Bioscience's market cap for the quarter that ended in May. 2026 was $14.92 Mil.
Lexaria Bioscience's quarterly market cap
declined
from Nov. 2025 ($24.23 Mil) to Feb. 2026 ($17.40 Mil) and
declined
from Feb. 2026 ($17.40 Mil) to May. 2026 ($14.92 Mil).
Lexaria Bioscience's annual market cap
increased
from Aug. 2023 ($8.50 Mil) to Aug. 2024 ($61.82 Mil) but then
declined
from Aug. 2024 ($61.82 Mil) to Aug. 2025 ($17.22 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Lexaria Bioscience's Enterprise Value for Today is $9.46 Mil.
Lexaria Bioscience (NAS:LEXX) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Lexaria Bioscience Market Cap Related Terms
Lexaria Bioscience Market Cap Historical Data
* Premium members only.
The historical data trend for Lexaria Bioscience's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lexaria Bioscience's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lexaria Bioscience Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Market Cap distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Lexaria Bioscience's Market Cap for the fiscal year that ended in Aug. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience (LEXX) has a Market Cap of $13.39 Mil as of Jul. 28, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lexaria Bioscience and its competitors. According to the industry distribution chart, Lexaria Bioscience ranks #1162 out of 1420 companies in the Biotechnology industry, placing it in the top 81.8%.
Is Lexaria Bioscience's Market Cap too high?
Lexaria Bioscience's current Market Cap is $13.39 Mil. The Biotechnology industry median Market Cap is 111.98. Lexaria Bioscience's value of $13.39 Mil is 88% below this industry median. Based on the distribution chart, Lexaria Bioscience ranks #1162 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lexaria Bioscience has a GF Score™ of 22/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Lexaria Bioscience's Market Cap compare to CTXR and PTN?
According to the Biotechnology industry distribution chart, Lexaria Bioscience ranks #1162 out of 1420 companies for Market Cap. This places Lexaria Bioscience in the lower half of its industry. The industry median Market Cap is 111.98. Lexaria Bioscience's value of $13.39 Mil is 88% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.98, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lexaria Bioscience's current Market Cap of $13.39 Mil is 88% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Lexaria Bioscience and its competitors. For the Biotechnology industry, the median Market Cap is 111.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lexaria Bioscience's current Market Cap is $13.39 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lexaria Bioscience stock overvalued right now?
Based on GuruFocus' analysis, Lexaria Bioscience (LEXX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.37, compared to a current price of $0.54 — trading 46% above its estimated fair value. The current Market Cap is $13.39 Mil and 88% below the Biotechnology industry median of 111.98. Lexaria Bioscience's overall GF Score™ is 22/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Lexaria Bioscience (LEXX), the current Market Cap is $13.39 Mil as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lexaria Bioscience (LEXX) Overvalued in 2026?
Based on GuruFocus' analysis, Lexaria Bioscience stock appears to be overvalued.
The current stock price of $0.54 is trading 46% above its estimated GF Value™ of $0.37.
GuruFocus considers Lexaria Bioscience to be Significantly Overvalued.
Key valuation signals for LEXX:
Market Cap: $13.39 Mil
GF Value™: $0.37 vs. price of $0.54 (46% above fair value)
Industry Position: 88% below the Biotechnology median (#1162 of 1420)
No single metric tells the full story. See the LEXX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lexaria Bioscience Corp is a biotechnology company focused on enhancing the bioavailability of active pharmaceutical ingredients using its patented DehydraTECH drug delivery technology. DehydraTECH improves absorption, effectiveness, and tolerability and can be applied to APIs such as GLP-1 and GIP drugs, vitamins, pain medications, hormones, antivirals, nicotine and cannabinoids across therapeutic areas including diabetes, weight loss, epilepsy, hypertension, and heart disease. It can be used in formats such as tablets, capsules, oral suspensions, foods, beverages, and pouches, and supports pharmaceuticals, nutraceuticals, over-the-counter products, and consumer packaged goods. The Company operates one segment: IP licensing, generating revenue from licensing its DehydraTECH technology.
22GF Score
Get the complete analysis for LEXX
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEXX has been successfully added to your 
